Weiss Ratings Reiterates Sell (E+) Rating for Reviva Pharmaceuticals (NASDAQ:RVPH)

Key Points

• Weiss Ratings has reaffirmed a "Sell (E+)" rating for Reviva Pharmaceuticals (NASDAQ:RVPH), indicating ongoing concerns about the company's performance.
• Despite Weiss's negative outlook, other analysts, including Citigroup and Roth Capital, maintain "Buy" ratings, suggesting a divergence in sentiment among investors.
• Reviva Pharmaceuticals currently has a market capitalization of $47.09 million, with a one-year stock price range from $0.25 to $4.28.

Reviva Pharmaceuticals (NASDAQ:RVPH - Get Free Report)'s stock had its "sell (e+)" rating reissued by analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

A number of other equities research analysts also recently weighed in on RVPH. Citigroup reiterated a "buy" rating on shares of Reviva Pharmaceuticals in a report on Friday, August 15th. D. Boral Capital lowered their target price on Reviva Pharmaceuticals from $3.00 to $2.00 and set a "buy" rating for the company in a report on Friday, September 19th. Roth Capital reiterated a "buy" rating and issued a $3.00 target price (down from $7.00) on shares of Reviva Pharmaceuticals in a report on Monday, August 18th. Benchmark lowered their target price on Reviva Pharmaceuticals from $14.00 to $7.00 and set a "speculative buy" rating for the company in a report on Monday, September 15th. Finally, Maxim Group lowered their target price on Reviva Pharmaceuticals from $5.00 to $2.00 and set a "buy" rating for the company in a report on Friday, August 15th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $4.86.

Reviva Pharmaceuticals Price Performance

Shares of RVPH opened at $0.68 on Wednesday. Reviva Pharmaceuticals has a 1 year low of $0.25 and a 1 year high of $4.28. The company has a market capitalization of $47.09 million, a price-to-earnings ratio of -1.04 and a beta of -0.08. The business has a 50-day moving average of $0.45 and a 200-day moving average of $0.62.

Reviva Pharmaceuticals (NASDAQ:RVPH - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.03. As a group, sell-side analysts anticipate that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. BluePointe Capital Management LLC grew its stake in Reviva Pharmaceuticals by 354.7% in the first quarter. BluePointe Capital Management LLC now owns 47,185 shares of the company's stock valued at $45,000 after acquiring an additional 36,807 shares during the period. NewEdge Advisors LLC acquired a new stake in Reviva Pharmaceuticals in the first quarter valued at approximately $58,000. XTX Topco Ltd acquired a new stake in Reviva Pharmaceuticals in the second quarter valued at approximately $31,000. Private Advisor Group LLC acquired a new stake in Reviva Pharmaceuticals in the first quarter valued at approximately $191,000. Finally, Geode Capital Management LLC grew its stake in Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company's stock valued at $171,000 after acquiring an additional 29,063 shares during the period. Institutional investors and hedge funds own 63.18% of the company's stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.